Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

University of Southampton's Dr Miriam Santer will conduct a new study to test whether Spironolactone, which is usually given to people for high blood pressure, is effective in treating acne.

Spironolactone has been used off-license in acne affecting women for over 30 years. Yet, there is no robust evidence that it works. It is thought to lower hormones that trigger grease production by the skin. In acne, the skin produces more grease than normal, so some dermatologists think that spironolactone can help treat acne.

The £1.7million study is being funded by the National Institute for Health Research Health Technology Assessment (HTA) programme. The story has been covered by
Heart FM.

Dr Santer works closely with Dr Matthew Ridd and other members of the School who are part of the Allergy working group. She is also PI for a prestigious NIHR PGfAR five year study to explore the best ways of supporting eczema self-management using online technology.

She has received funding from the School in the past for the Trial of Eczema allergy Trial (TEST) which considers the role food allergy tests play in treating eczema.

Most recently, Miriam has received funding to investigate the possible role of Andrographis paniculata as a symptomatic intervention for acute respiratory tract infections